Lista de obras -

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers

artículo científico publicado en 2018

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer ⬇️

artículo científico publicado el 14 de octubre de 2010

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

artículo científico publicado en 2016

A response to "Personalised medicine and population health: breast and ovarian cancer"

artículo científico publicado en 2019

A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population

artículo científico publicado en 2020

Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial

scholarly article

Abstract 2985: Predicting the impact of mutations in cancer using an integrated pathway approach

Abstract 3314: Normal breast tissue at risk for cancer development: A breast cancer initiating role for mammary adipocytes

scholarly article

Abstract 3361: A prescription for new trial designs for drug development focused on the neoadjuvant setting: Save lives, resources, and time

scholarly article

Abstract 5402: A new anticancer strategy based on inhibiting mitochondrial proline dehydrogenase (PRODH) and exploiting synthetic lethal interactions with p53 restoration and/or glutaminase (GLS1) inhibition

artículo científico publicado en 2015

Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.

artículo científico publicado en 2005

Adaptive Randomization of Neratinib in Early Breast Cancer

artículo científico publicado en 2016

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer

artículo científico publicado en 2016

Ageing, oxidative stress and cancer: paradigms in parallax

artículo científico publicado en 2008

Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers

artículo científico publicado en 2007

An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer.

artículo científico publicado en 2016

An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk

artículo científico publicado en 2013

Androgen receptor gene expression in primary breast cancer

scientific article published on 10 December 2019

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer

scientific article published on 08 August 2019

Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical T

scientific article published on 23 July 2020

Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial

artículo científico publicado en 2022

Biologic markers determine both the risk and the timing of recurrence in breast cancer ⬇️

artículo científico publicado el 20 de mayo de 2011

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

artículo científico publicado en 2018

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

artículo científico publicado en 2011

Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) ⬇️

artículo científico publicado el 19 de junio de 2013

Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer

artículo científico publicado en 2016

Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

artículo científico publicado en 2017

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

artículo científico

Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer

scientific article published on 01 May 2020

Comprehensive Characterization of Cancer Driver Genes and Mutations

article

Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer

artículo científico publicado en 2015

DGCR8 is essential for tumor progression following PTEN loss in the prostate

artículo científico publicado en 2015

DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas

artículo científico publicado en 2016

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial

artículo científico publicado en 2017

Discovery of internalizing antibodies to basal breast cancer cells

artículo científico publicado en 2017

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

artículo científico publicado en 2020

Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer

artículo científico publicado en 2007

Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL

scientific article published on 16 August 2018

FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index

artículo científico publicado en 2015

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.

artículo científico publicado en 2017

First Pregnancy Characteristics, Postmenopausal Breast Density, and Salivary Sex Hormone Levels in a Population at High Risk for Breast Cancer

artículo científico publicado en 2015

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

artículo científico publicado en 2021

Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity

artículo científico publicado en 2014

Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers

artículo científico publicado en 2008

Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

artículo científico publicado en 2018

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

artículo científico publicado en 2018

High-Throughput Kinase Activity Mapping (HT-KAM) system: analysis of phospho-catalytic profiles

scholarly article

Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial

artículo científico publicado en 2024

Integrated genomic characterization of endometrial carcinoma ⬇️

artículo científico publicado el 2 de mayo de 2013

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma

artículo científico publicado en 2017

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma

artículo científico publicado en 2018

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer

artículo científico publicado en 2018

Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.

artículo científico publicado en 2014

Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.

artículo científico publicado en 2012

Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

artículo científico publicado en 2014

Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial) ⬇️

artículo científico publicado el 28 de julio de 2011

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial

artículo científico publicado en 2019

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities

scientific article published on 03 June 2019

Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial

artículo científico publicado en 2020

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin

artículo científico publicado en 2014

Novel pathways associated with quinone-induced stress in breast cancer cells

artículo científico publicado en 2006

PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression

artículo científico publicado en 2016

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial

artículo científico publicado en 2021

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

artículo científico publicado en 2012

Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer

artículo científico publicado en 2007

RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth

artículo científico publicado en 2014

Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).

artículo científico publicado en 2017

Response to Carter et al

artículo científico publicado en 2020

Rethinking the Standard for Ductal Carcinoma In Situ Treatment

artículo científico publicado en 2015

Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer ⬇️

artículo científico publicado el 17 de marzo de 2011

Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response

artículo científico publicado en 2015

Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer

artículo científico publicado en 2019

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

artículo científico publicado en 2017

Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition

artículo científico publicado en 2019

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

artículo científico publicado en 2017

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

article

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

artículo científico publicado en 2015

The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches

artículo científico publicado en 2018

The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context

artículo científico publicado en 2013

Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply.

artículo científico publicado en 2016

Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis

artículo científico publicado en 2020

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.

artículo científico publicado en 2017

Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway

artículo científico publicado en 2021

Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers ⬇️

artículo científico publicado el 12 de enero de 2011

Lista de obras de

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer ⬇️

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

A response to "Personalised medicine and population health: breast and ovarian cancer"

A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population

Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial

Abstract 2985: Predicting the impact of mutations in cancer using an integrated pathway approach

Abstract 3314: Normal breast tissue at risk for cancer development: A breast cancer initiating role for mammary adipocytes

Abstract 3361: A prescription for new trial designs for drug development focused on the neoadjuvant setting: Save lives, resources, and time

Abstract 5402: A new anticancer strategy based on inhibiting mitochondrial proline dehydrogenase (PRODH) and exploiting synthetic lethal interactions with p53 restoration and/or glutaminase (GLS1) inhibition

Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.

Adaptive Randomization of Neratinib in Early Breast Cancer

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer

Ageing, oxidative stress and cancer: paradigms in parallax

Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers

An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer.

An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk

Androgen receptor gene expression in primary breast cancer

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer

Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical T

Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial

Biologic markers determine both the risk and the timing of recurrence in breast cancer ⬇️

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) ⬇️

Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer

Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer

Comprehensive Characterization of Cancer Driver Genes and Mutations

Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer

DGCR8 is essential for tumor progression following PTEN loss in the prostate

DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial

Discovery of internalizing antibodies to basal breast cancer cells

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer

Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL

FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.

First Pregnancy Characteristics, Postmenopausal Breast Density, and Salivary Sex Hormone Levels in a Population at High Risk for Breast Cancer

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity

Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers

Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

High-Throughput Kinase Activity Mapping (HT-KAM) system: analysis of phospho-catalytic profiles

Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial

Integrated genomic characterization of endometrial carcinoma ⬇️

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer

Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.

Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.

Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial) ⬇️

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities

Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin

Novel pathways associated with quinone-induced stress in breast cancer cells

PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer

RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth

Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).

Response to Carter et al

Rethinking the Standard for Ductal Carcinoma In Situ Treatment

Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer ⬇️

Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response

Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches

The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context